Result of General Meeting

MicroSalt PLC

02 October 2026

MicroSalt Plc

("MicroSalt" or the "Company")

Result of General Meeting

MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt with approximately 50% less sodium, announces the results of its General Meeting (“GM”), held earlier today.

All six resolutions put to members were duly passed, with the number of votes cast for, against and withheld as follows:

	For	Against			Votes Withheld				Total Votes Cast
	Number of Votes	%	Number of Votes			%	Number of Votes
Ordinary Resolutions
1. To authorise the Directors to allot Ordinary Shares for cash in relation to the Fundraise up to an aggregate nominal amount of £10,400.00.	33,812,111	99.14%		294,741		0.86%		151,509		34,106,852
2. To authorise the Directors to allot Ordinary Shares for cash in connection with the exercise of convertible loan notes issued prior to the date of this resolution up to an aggregate nominal amount of £4,550.00.	33,898,226	99.39%		208,486		0.61%		151,649		34,106,712
3. To authorise the Directors to allot Ordinary Shares for cash up to an aggregate nominal amount of £23,918.41 (being approximately 20% of the Enlarged Share Capital).	33,812,617	99.14%		294,235		0.86%		151,509		34,106,852
Special Resolutions
4. Subject to the passing of Resolution 1, to authorise the Directors to disapply pre-emption rights granted to Shareholders pursuant to the Act, in respect of the allotment and issue of the Fundraising Shares.	33,893,531	99.37%		214,821		0.63%		150,009		34,108,352
5. Subject to the passing of Resolution 2, to authorise the Directors to disapply pre-emption rights granted to Shareholders pursuant to the Act, in respect of the allotment and issue of Ordinary Shares allotted and issued on connection with the exercise of convertible loan notes issued prior to the date of this resolution.	33,885,983	99.35%		222,369		0.65%		150,009		34,108,352
6. Subject to the passing of Resolution 3, to authorise the Directors to disapply pre-emption rights granted to Shareholders pursuant to the Act, in respect of the allotment and issue of Ordinary Shares up to an aggregate amount of £23,918.41 (being approximately 20% of the Enlarged Share Capital).	33,789,376	99.06%		318,976		0.94%		150,009		34,108,352

Enquiries:

MicroSalt plc	Via Gracechurch Group
Rick Guiney (CEO) Gary Urmston, Interim CFO

Zeus (Nominated Adviser and Broker)	+44 (0)20 3829 5000
David Foreman / Ed Beddows (Investment Banking) Nick Searle (Head of Equity Capital Markets)

Gracechurch Group (Financial PR)	+44 (0)20 4582 3500
Heather Armstrong, Alexis Gore, Rebecca Scott

About MicroSalt

MicroSalt is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges.

Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year.

For more information, please visit www.microsaltinc.co or follow on X @microSaltPLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END